Authors
Loading...
Observational analysis reveals Yap1's potential as a biomarker in pan-cancer, indicating significant mutation frequencies.
Yufan Xu (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: